The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Spravato is classified as a Schedule III controlled substance and ... Improvements were observed approximately 24 hours after the first dose of Spravato and were sustained through 4 weeks of ...

The latter compound has already been approved for treatment-resistance depression as the product Spravato (esketamine ... that patients taking a higher dose version of its treatment demonstrated ...

In the latter trial, 29.1% of patients receiving a 25mg dose were in remission at week ... behind each treatment mentioned listed as Schedule I substances, meaning that they are considered to ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

total score within 24 hours after the initial dose, with effects sustained for at least four weeks. Spravato’s safety profile aligns with existing data for oral antidepressants, with no new ...

SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's ...